Annalisa Jenkins

Perspectum Group Plc engages in the sale of diagnostic products via a software-as-a-medical device platform. Its products combine expertise in image formation, magnetic resonance image analysis and artificial intelligence to support healthcare provider diagnosis, treatment decision-making, and monitoring of the progression of chronic metabolic diseases, multi-organ pathologies and cancer, and determine whether the patient is responding to therapy. Its products include Liver MultiScan, MRCP+, Hepatica, and CoverScan MD. The company was founded by Matthew Robson on June 10, 2021 and is headquartered in Oxford, the United Kingdom.

Perspectum Ltd. provides technology solutions for diagnosing and staging liver disease. The company was founded by Rajarshi Banerjee, Stefan Karl Neubauer, Matthew David Robson, Alastair Cavanagh, James Hugh Charteris Mallinson and John Michael Brady on September 18, 2012 and is headquartered in Oxford, the United Kindgom.

Kuur Therapeutics provides clinical cellular therapeutics services. It develops, manufactures and markets personalized cellular immunotherapeutics for infectious disease and cancer. Cell Medica has developed proprietary production technology enabling GMP compliant manufacture of antigen-specific T cells. The company was founded by Gregg Sando in 2006 and is headquartered in London, the United Kingdom.

Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010.

Cocoon Biotech, Inc. develops and manufactures medicines for osteoarthritis patients. The company was founded by Ailis Tweed-Kent in 2013 and is headquartered in Cambridge, MA.

Part of Compass Pathways Plc, COMPASS Pathfinder Holdings Ltd. is an investment holding British company. The company is based in London, UK and was founded in 2017.

Part of Compass Pathways Plc, COMPASS Pathfinder Holdings Ltd. is an investment holding British company. The company is based in London, UK and was founded in 2017.

Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010.

Oncimmune Ltd. provides clinical testing services for cancer detection. The firm develops early cancer detection tests for lung, breast, colorectal, prostate, stomach, pancreatic and ovarian cancers. The company was founded by John F. R. Robertson in 2003 and is headquartered in Nottingham, the United Kingdom.

Part of Compass Pathways Plc, COMPASS Pathfinder Holdings Ltd. is an investment holding British company. The company is based in London, UK and was founded in 2017.

Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010.

Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010.

Cocoon Biotech, Inc. develops and manufactures medicines for osteoarthritis patients. The company was founded by Ailis Tweed-Kent in 2013 and is headquartered in Cambridge, MA.

Perspectum Ltd. provides technology solutions for diagnosing and staging liver disease. The company was founded by Rajarshi Banerjee, Stefan Karl Neubauer, Matthew David Robson, Alastair Cavanagh, James Hugh Charteris Mallinson and John Michael Brady on September 18, 2012 and is headquartered in Oxford, the United Kindgom.

Perspectum Ltd. provides technology solutions for diagnosing and staging liver disease. The company was founded by Rajarshi Banerjee, Stefan Karl Neubauer, Matthew David Robson, Alastair Cavanagh, James Hugh Charteris Mallinson and John Michael Brady on September 18, 2012 and is headquartered in Oxford, the United Kindgom.

Perspectum Group Plc engages in the sale of diagnostic products via a software-as-a-medical device platform. Its products combine expertise in image formation, magnetic resonance image analysis and artificial intelligence to support healthcare provider diagnosis, treatment decision-making, and monitoring of the progression of chronic metabolic diseases, multi-organ pathologies and cancer, and determine whether the patient is responding to therapy. Its products include Liver MultiScan, MRCP+, Hepatica, and CoverScan MD. The company was founded by Matthew Robson on June 10, 2021 and is headquartered in Oxford, the United Kingdom.

Oncimmune Ltd. provides clinical testing services for cancer detection. The firm develops early cancer detection tests for lung, breast, colorectal, prostate, stomach, pancreatic and ovarian cancers. The company was founded by John F. R. Robertson in 2003 and is headquartered in Nottingham, the United Kingdom.

Genomics England Ltd. runs and delivers 100,000 genomes project. Its flagship project sequences 100,000 genomes from NHS patients with a rare disease and their families, and patients with cancer. The company was founded by Jeremy Hunt on July 5, 2013 and is headquartered in London, the United Kingdom.

Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010.

Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010.

Coqual, formerly known as the Center for Talent Innovation, is a nonprofit think tank that helps leaders create diverse, equitable, and inclusive workplaces. The non-profit company is based in New York, NY, and was founded by Sylvia Ann Hewlett. The company focuses on conducting cutting-edge research and providing advisory services on various identities, including gender, race, ethnicity, disability, veteran status, and LGBTQ. Coqual was founded in 2004 and offers in-depth research, thought leadership, and data-driven solutions to address bias and barriers to inclusion for underrepresented populations in the workplace. Lanaya Irvin has been the CEO of the company since 2020.

Part of Leadership Foundations, Women's Forum, Inc. is a non-profit community for women leaders of diverse achievement. The company is based in New York, NY.

Genomics England Ltd. runs and delivers 100,000 genomes project. Its flagship project sequences 100,000 genomes from NHS patients with a rare disease and their families, and patients with cancer. The company was founded by Jeremy Hunt on July 5, 2013 and is headquartered in London, the United Kingdom.

Coqual, formerly known as the Center for Talent Innovation, is a nonprofit think tank that helps leaders create diverse, equitable, and inclusive workplaces. The non-profit company is based in New York, NY, and was founded by Sylvia Ann Hewlett. The company focuses on conducting cutting-edge research and providing advisory services on various identities, including gender, race, ethnicity, disability, veteran status, and LGBTQ. Coqual was founded in 2004 and offers in-depth research, thought leadership, and data-driven solutions to address bias and barriers to inclusion for underrepresented populations in the workplace. Lanaya Irvin has been the CEO of the company since 2020.

Perspectum Group Plc engages in the sale of diagnostic products via a software-as-a-medical device platform. Its products combine expertise in image formation, magnetic resonance image analysis and artificial intelligence to support healthcare provider diagnosis, treatment decision-making, and monitoring of the progression of chronic metabolic diseases, multi-organ pathologies and cancer, and determine whether the patient is responding to therapy. Its products include Liver MultiScan, MRCP+, Hepatica, and CoverScan MD. The company was founded by Matthew Robson on June 10, 2021 and is headquartered in Oxford, the United Kingdom.

Perspectum Ltd. provides technology solutions for diagnosing and staging liver disease. The company was founded by Rajarshi Banerjee, Stefan Karl Neubauer, Matthew David Robson, Alastair Cavanagh, James Hugh Charteris Mallinson and John Michael Brady on September 18, 2012 and is headquartered in Oxford, the United Kindgom.

RYSE Asset Management LLP (RYSE) is a venture capital firm founded in 2010 by Atique Mirza. The firm is headquartered in London, the United Kingdom.

Oncimmune Ltd. provides clinical testing services for cancer detection. The firm develops early cancer detection tests for lung, breast, colorectal, prostate, stomach, pancreatic and ovarian cancers. The company was founded by John F. R. Robertson in 2003 and is headquartered in Nottingham, the United Kingdom.

Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010.

AOBiome Therapeutics, Inc. develops microbiome-targeted therapies for local, nasal and systemic inflammatory conditions. Its portfolio includes three clinical-stage programs, a Phase 2b study to treat patients with acne vulgaris, a Phase 2 trial to reduce elevated blood pressure, and a Phase 1b/2a clinical trial in allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications. The company was founded by Jamie Heywood, David Whitlock and Lenny Barshack in 2013 and is headquartered in Cambridge, MA.

AOBiome Therapeutics, Inc. develops microbiome-targeted therapies for local, nasal and systemic inflammatory conditions. Its portfolio includes three clinical-stage programs, a Phase 2b study to treat patients with acne vulgaris, a Phase 2 trial to reduce elevated blood pressure, and a Phase 1b/2a clinical trial in allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications. The company was founded by Jamie Heywood, David Whitlock and Lenny Barshack in 2013 and is headquartered in Cambridge, MA.

Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010.

Perspectum Group Plc engages in the sale of diagnostic products via a software-as-a-medical device platform. Its products combine expertise in image formation, magnetic resonance image analysis and artificial intelligence to support healthcare provider diagnosis, treatment decision-making, and monitoring of the progression of chronic metabolic diseases, multi-organ pathologies and cancer, and determine whether the patient is responding to therapy. Its products include Liver MultiScan, MRCP+, Hepatica, and CoverScan MD. The company was founded by Matthew Robson on June 10, 2021 and is headquartered in Oxford, the United Kingdom.

Perspectum Ltd. provides technology solutions for diagnosing and staging liver disease. The company was founded by Rajarshi Banerjee, Stefan Karl Neubauer, Matthew David Robson, Alastair Cavanagh, James Hugh Charteris Mallinson and John Michael Brady on September 18, 2012 and is headquartered in Oxford, the United Kindgom.

AOBiome Therapeutics, Inc. develops microbiome-targeted therapies for local, nasal and systemic inflammatory conditions. Its portfolio includes three clinical-stage programs, a Phase 2b study to treat patients with acne vulgaris, a Phase 2 trial to reduce elevated blood pressure, and a Phase 1b/2a clinical trial in allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications. The company was founded by Jamie Heywood, David Whitlock and Lenny Barshack in 2013 and is headquartered in Cambridge, MA.

Part of Leadership Foundations, Women's Forum, Inc. is a non-profit community for women leaders of diverse achievement. The company is based in New York, NY.

Genomics England Ltd. runs and delivers 100,000 genomes project. Its flagship project sequences 100,000 genomes from NHS patients with a rare disease and their families, and patients with cancer. The company was founded by Jeremy Hunt on July 5, 2013 and is headquartered in London, the United Kingdom.

Part of Leadership Foundations, Women's Forum, Inc. is a non-profit community for women leaders of diverse achievement. The company is based in New York, NY.

PhESi LLC provides drug and clinical development services for life sciences companies. The private company is based in East Lyme.

Oncimmune Ltd. provides clinical testing services for cancer detection. The firm develops early cancer detection tests for lung, breast, colorectal, prostate, stomach, pancreatic and ovarian cancers. The company was founded by John F. R. Robertson in 2003 and is headquartered in Nottingham, the United Kingdom.

Perspectum Ltd. provides technology solutions for diagnosing and staging liver disease. The company was founded by Rajarshi Banerjee, Stefan Karl Neubauer, Matthew David Robson, Alastair Cavanagh, James Hugh Charteris Mallinson and John Michael Brady on September 18, 2012 and is headquartered in Oxford, the United Kindgom.

Perspectum Group Plc engages in the sale of diagnostic products via a software-as-a-medical device platform. Its products combine expertise in image formation, magnetic resonance image analysis and artificial intelligence to support healthcare provider diagnosis, treatment decision-making, and monitoring of the progression of chronic metabolic diseases, multi-organ pathologies and cancer, and determine whether the patient is responding to therapy. Its products include Liver MultiScan, MRCP+, Hepatica, and CoverScan MD. The company was founded by Matthew Robson on June 10, 2021 and is headquartered in Oxford, the United Kingdom.

Genomics England Ltd. runs and delivers 100,000 genomes project. Its flagship project sequences 100,000 genomes from NHS patients with a rare disease and their families, and patients with cancer. The company was founded by Jeremy Hunt on July 5, 2013 and is headquartered in London, the United Kingdom.

Perspectum Group Plc engages in the sale of diagnostic products via a software-as-a-medical device platform. Its products combine expertise in image formation, magnetic resonance image analysis and artificial intelligence to support healthcare provider diagnosis, treatment decision-making, and monitoring of the progression of chronic metabolic diseases, multi-organ pathologies and cancer, and determine whether the patient is responding to therapy. Its products include Liver MultiScan, MRCP+, Hepatica, and CoverScan MD. The company was founded by Matthew Robson on June 10, 2021 and is headquartered in Oxford, the United Kingdom.

Perspectum Ltd. provides technology solutions for diagnosing and staging liver disease. The company was founded by Rajarshi Banerjee, Stefan Karl Neubauer, Matthew David Robson, Alastair Cavanagh, James Hugh Charteris Mallinson and John Michael Brady on September 18, 2012 and is headquartered in Oxford, the United Kindgom.

Viventia Bio, Inc. operates as a biologics oncology company, which focuses on designing, engineering, and developing targeted protein therapeutics. The company was founded by Leslie Lewis Dan in October 2012 and is headquartered in Winnipeg, Canada.

Viventia Biotech, Inc. discovers, develops, manufactures, and commercializes monoclonal antibody products. Its products are used to treat head, neck, and bladder cancers. The company was founded by Albert D. Friesen in 1995 and is headquartered in Toronto, Canada

Viventia Biotech, Inc. discovers, develops, manufactures, and commercializes monoclonal antibody products. Its products are used to treat head, neck, and bladder cancers. The company was founded by Albert D. Friesen in 1995 and is headquartered in Toronto, Canada

Genomics England Ltd. runs and delivers 100,000 genomes project. Its flagship project sequences 100,000 genomes from NHS patients with a rare disease and their families, and patients with cancer. The company was founded by Jeremy Hunt on July 5, 2013 and is headquartered in London, the United Kingdom.